Sec Form 4 Filing - Moore Terrence O @ ACADIA PHARMACEUTICALS INC - 2017-02-14

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Moore Terrence O
2. Issuer Name and Ticker or Trading Symbol
ACADIA PHARMACEUTICALS INC [ ACAD]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
EVP, CHIEF COMMERCIAL OFFICER
(Last) (First) (Middle)
3611 VALLEY CENTRE DRIVE, SUITE 300
3. Date of Earliest Transaction (MM/DD/YY)
02/14/2017
(Street)
SAN DIEGO, CA92130
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/14/2017 M 87,128 A $ 19.61 90,759 ( 1 ) D
Common Stock 02/14/2017 S( 2 ) 89,088 D $ 39.6863 ( 3 ) 1,671 D
Common Stock 02/15/2017 M 1,700 A $ 19.61 3,371 D
Common Stock 02/15/2017 S( 2 ) 1,700 D $ 39.65 1,671 D
Common Stock 02/16/2017 M 17,421 A $ 19.61 19,092 D
Common Stock 02/16/2017 M 19,687 A $ 27.2 38,779 D
Common Stock 02/16/2017 M 29,644 A $ 34.45 68,423 D
Common Stock 02/16/2017 S( 2 ) 66,752 D $ 39.8807 ( 4 ) 1,671 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $ 19.61 02/14/2017 M 12,747 ( 5 ) 08/18/2023 Common Stock 12,747 $ 0 7,649 D
Stock Option (right to buy) $ 19.61 02/14/2017 M 74,381 ( 5 ) 08/18/2023 Common Stock 74,381 $ 0 55,223 D
Stock Option (right to buy) $ 19.61 02/15/2017 M 1,700 ( 5 ) 08/18/2023 Common Stock 1,700 $ 0 53,523 D
Stock Option (right to buy) $ 19.61 02/16/2017 M 17,421 ( 5 ) 08/18/2023 Common Stock 17,421 $ 0 36,102 D
Stock Option (right to buy) $ 27.2 02/16/2017 M 19,687 ( 6 ) 03/06/2024 Common Stock 19,687 $ 0 13,125 D
Stock Option (right to buy) $ 34.35 02/16/2017 M 29,644 ( 7 ) 03/19/2025 Common Stock 29,644 $ 0 90,356 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Moore Terrence O
3611 VALLEY CENTRE DRIVE, SUITE 300
SAN DIEGO, CA92130
EVP, CHIEF COMMERCIAL OFFICER
Signatures
/s/ Elizabeth Carter, Attorney-in-Fact 02/16/2017
Signature of Reporting Person Date
Explanation of Responses:
( 1 )Includes 717, 1,243, 461 and 1,210 shares acquired in November 2014, May 2015, November 2015 and May 2016, respectively, by Mr. Moore under the ACADIA Pharmaceuticals Employee Stock Purchase Plan, as amended.
( 2 )The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2015, as amended in June 2016.
( 3 )The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $39.72 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuti cals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
( 4 )The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $40.38 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
( 5 )25% of the shares subject to the Stock Option vested and became exercisable on August 19, 2014. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.
( 6 )25% of the shares subject to the Stock Option vested and became exercisable on March 7, 2015. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.
( 7 )25% of the shares subject to the Stock Option vested and became exercisable on March 20, 2016. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.